Cantor Fitzgerald Forecasts CATX FY2026 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX) – Equities researchers at Cantor Fitzgerald issued their FY2026 earnings estimates for Perspective Therapeutics in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek forecasts that the company will post earnings of ($0.99) per share for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share.

Several other research firms also recently issued reports on CATX. Brookline Capital Management upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. Royal Bank of Canada upgraded Perspective Therapeutics from an “outperform” rating to a “moderate buy” rating and boosted their price objective for the stock from $15.00 to $16.00 in a report on Tuesday, June 3rd. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Thursday, March 6th. Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, May 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Perspective Therapeutics in a research note on Monday, March 31st. One analyst has rated the stock with a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, Perspective Therapeutics currently has an average rating of “Buy” and an average target price of $12.63.

Perspective Therapeutics Stock Performance

NYSE CATX opened at $3.43 on Tuesday. The stock’s 50-day moving average price is $2.39 and its two-hundred day moving average price is $2.87. Perspective Therapeutics has a 1 year low of $1.60 and a 1 year high of $16.55.

Insider Buying and Selling at Perspective Therapeutics

In other news, Director Robert F. Williamson III purchased 22,192 shares of the stock in a transaction that occurred on Friday, March 28th. The stock was acquired at an average price of $2.27 per share, with a total value of $50,375.84. Following the purchase, the director now owns 70,837 shares in the company, valued at $160,799.99. This represents a 45.62% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Johan M. Spoor purchased 22,026 shares of the stock in a transaction that occurred on Friday, March 28th. The stock was purchased at an average cost of $2.24 per share, with a total value of $49,338.24. Following the purchase, the chief executive officer now owns 59,383 shares in the company, valued at $133,017.92. This represents a 58.96% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 115,696 shares of company stock valued at $256,344 in the last 90 days. 3.72% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Perspective Therapeutics

Several large investors have recently made changes to their positions in the company. Affinity Asset Advisors LLC grew its stake in shares of Perspective Therapeutics by 71.1% in the 1st quarter. Affinity Asset Advisors LLC now owns 2,224,196 shares of the company’s stock valued at $4,738,000 after buying an additional 924,196 shares in the last quarter. MetLife Investment Management LLC boosted its position in Perspective Therapeutics by 40.9% during the first quarter. MetLife Investment Management LLC now owns 31,310 shares of the company’s stock worth $67,000 after purchasing an additional 9,082 shares during the period. HighTower Advisors LLC boosted its position in Perspective Therapeutics by 13.2% during the first quarter. HighTower Advisors LLC now owns 201,586 shares of the company’s stock worth $429,000 after purchasing an additional 23,475 shares during the period. Nuveen LLC bought a new stake in Perspective Therapeutics during the first quarter worth approximately $2,647,000. Finally, Charles Schwab Investment Management Inc. boosted its position in Perspective Therapeutics by 6.7% during the first quarter. Charles Schwab Investment Management Inc. now owns 434,085 shares of the company’s stock worth $925,000 after purchasing an additional 27,119 shares during the period. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.